In Vitro Antimicrobial Susceptibility Testing of Biofilm-Growing Bacteria: Current and Emerging Methods

Bonaventura, Giovanni Di; Pompilio, Arianna

doi:10.1007/5584_2021_641

Cited by 8 publications

(6 citation statements)

References 144 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We investigated the in vitro antibacterial effect of PRF in monocultures. However, most bacteria in the oral cavity grow in biofilms, which would require higher minimal inhibitory concentrations for treatment [ 39 ]. Further studies should therefore investigate whether the antibacterial effects of antibiotic-enriched PRF are sufficient to penetrate oral biofilms, thus preventing and fighting infections in vivo.…”

Section: Discussionmentioning

confidence: 99%

Investigation of three common centrifugation protocols for platelet-rich fibrin (PRF) as a bio-carrier for ampicillin/sulbactam: a prospective trial

Straub,

Utz,

Stapf

et al. 2023

Clin Oral Invest

View full text Add to dashboard Cite

Objectives Different platelet-rich fibrin (PRF) protocols exist and are known to differ in resulting mechanical and bioactive properties. Centrifugation parameters may also influence drug release, in particular antibiotics, when using PRF as a bio-carrier. We thus evaluated three common protocols regarding effects on the bio-carrier properties. Materials and methods In a prospective trial comprising 33 patients, we compared different protocols for PRF as a bio-carrier for ampicillin/sulbactam (SAM). Blood samples were taken shortly after a single dose of ampicillin/sulbactam (2 g/1 g) was administered to patients intravenously. PRF was obtained by centrifugation and three protocols were used: protocol A (1300 rpm, 8 min, RCF-max = 208 g), B (2300 rpm, 12 min, RCF-max = 652 g), and C (1500 rpm, 14 min, RCF-max = 276 g). The antibacterial activity of PRF was investigated against five oral species in vitro, based on agar diffusion methodology. Results The study demonstrates that a single dose of SAM is sufficient to reach high concentrations in PRF in all protocols (150 µg/ml), which is comparable to the plasma SAM concentration. Antibacterial activity was inferred from the diameter of inhibition zones seen in agar diffusion tests using PRF discs. Protocol B resulted in the largest inhibition zones. One-way ANOVA revealed statistically improved results for protocol B for some bacteria. Conclusions The study provides valuable data on PRF antibiotic enrichment, notably SAM. A single dose of SAM is sufficient to reach clinically relevant concentrations in PRF. Clinical relevance These findings potentially extend the application of PRF, for example in patients with osteonecrosis of the jaw or in oral surgery (e.g., stick bone).

show abstract

Section: Discussionmentioning

confidence: 99%

Investigation of three common centrifugation protocols for platelet-rich fibrin (PRF) as a bio-carrier for ampicillin/sulbactam: a prospective trial

Straub,

Utz,

Stapf

et al. 2023

Clin Oral Invest

View full text Add to dashboard Cite

show abstract

“…At present, K. pneumoniae has strong capsule and biofilm-forming ability. In the past 5 years, the formation rate of biofilm has increased year by year (16). The drug resistance of its strains is closely related to the formation of biofilm.…”

Section: Discussionmentioning

confidence: 99%

Formation ability and drug resistance mechanism of Klebsiella pneumoniae biofilm and capsule for multidrug-resistant

Jiayu Liang,

Shanshan Lin,

Lanbo He

2023

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

“…The results of the study detected a high rate of gram-negative isolates and a high rate of penicillin and ampicillin/sulbactam-resistant bacterial species. Considering that these bacteria grow in biofilms, which means higher MICs, the observed antibiotic bone concentrations may not be sufficient [ 34 , 35 , 36 ]. We have previously discussed the positive effect of PRF given its antibiotic load to increase the local antibiotic concentrations in the treatment of patients suffering from ONJ.…”

Section: Discussionmentioning

confidence: 99%

Bone Concentration of Ampicillin/Sulbactam: A Pilot Study in Patients with Osteonecrosis of the Jaw

Straub

Stapf

Fischer

et al. 2022

IJERPH

View full text Add to dashboard Cite

Osteonecrosis of the jaw (ONJ) occurs typically after irradiation of the head and neck area or after the intake of antiresorptive agents. Both interventions can lead to compromised bone perfusion and can ultimately result in infection and necrosis. Treatment usually consists of surgical necrosectomy and prolonged antibiotic therapy, usually through beta-lactams such as ampicillin/sulbactam. The poor blood supply in particular raises the question as to whether this form of antibiosis can achieve sufficient concentrations in the bone. Therefore, we investigated the antibiotic concentration in plasma and bone samples in a prospective study. Bone samples were collected from the necrosis core and in the vital surrounding bone. The measured concentrations in plasma for ampicillin and sulbactam were 126.3 ± 77.6 and 60.2 ± 35.0 µg/mL, respectively. In vital bone and necrotic bone samples, the ampicillin/sulbactam concentrations were 6.3 ± 7.8/1.8 ± 2.0 µg/g and 4.9 ± 7.0/1.7 ± 1.7 µg/g, respectively. These concentrations are substantially lower than described in the literature. However, the concentration seems sufficient to kill most bacteria, such as Streptococci and Staphylococci, which are mostly present in the biofilm of ONJ. We, therefore, conclude that intravenous administration of ampicillin/sulbactam remains a valuable treatment in the therapy of ONJ. Nevertheless, increasing resistance of Escherichia coli towards beta-lactam antibiotics have been reported and should be considered.

show abstract

In Vitro Antimicrobial Susceptibility Testing of Biofilm-Growing Bacteria: Current and Emerging Methods

Cited by 8 publications

References 144 publications

Investigation of three common centrifugation protocols for platelet-rich fibrin (PRF) as a bio-carrier for ampicillin/sulbactam: a prospective trial

Investigation of three common centrifugation protocols for platelet-rich fibrin (PRF) as a bio-carrier for ampicillin/sulbactam: a prospective trial

Formation ability and drug resistance mechanism of Klebsiella pneumoniae biofilm and capsule for multidrug-resistant

Bone Concentration of Ampicillin/Sulbactam: A Pilot Study in Patients with Osteonecrosis of the Jaw

Contact Info

Product

Resources

About